Profile data is unavailable for this security.
About the company
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
- Revenue in USD (TTM)788.90m
- Net income in USD75.90m
- Incorporated2003
- Employees900.00
- LocationEmergent BioSolutions Inc300 Professional DrGAITHERSBURG 20879United StatesUSA
- Phone+1 (240) 631-3200
- Fax+1 (240) 631-3203
- Websitehttps://emergentbiosolutions.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nika Pharmaceuticals Inc | 0.00 | -51.76k | 403.46m | -- | -- | -- | -- | -- | -0.00005 | -0.00005 | 0.00 | -0.0003 | 0.00 | -- | -- | -- | -413.75 | -21,428.06 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -47.74 | -- | -- | -- |
| Akebia Therapeutics Inc | 225.07m | -15.91m | 411.32m | 181.00 | -- | 9.88 | -- | 1.83 | -0.0761 | -0.0761 | 0.8951 | 0.1568 | 0.7879 | 2.08 | 4.57 | 1,243,486.00 | -5.57 | -38.92 | -8.55 | -61.07 | 81.89 | 71.93 | -7.07 | -76.49 | 1.80 | 0.7147 | 0.8219 | -- | -17.70 | -13.72 | -33.67 | -- | -65.40 | -- |
| Enanta Pharmaceuticals Inc | 66.98m | -71.54m | 413.51m | 120.00 | -- | 3.27 | -- | 6.17 | -3.20 | -3.20 | 2.89 | 4.36 | 0.1975 | -- | 8.26 | 558,166.70 | -21.10 | -26.15 | -24.48 | -29.36 | -- | -- | -106.80 | -134.68 | -- | -- | 0.5181 | -- | -3.42 | -11.81 | 29.43 | -- | 54.92 | -- |
| Eton Pharmaceuticals Inc | 70.32m | -6.68m | 430.42m | 31.00 | -- | 18.61 | -- | 6.12 | -0.2491 | -0.2491 | 2.63 | 0.8624 | 1.00 | 3.64 | 7.53 | 2,268,258.00 | -9.52 | -27.81 | -17.48 | -37.96 | 51.36 | 68.16 | -9.50 | -38.41 | 1.25 | 0.2114 | 0.5677 | -- | 23.29 | 109.83 | -308.44 | -- | 40.24 | -- |
| Invivyd Inc | 50.04m | -59.86m | 454.00m | 99.00 | -- | 3.71 | -- | 9.07 | -0.4736 | -0.4736 | 0.3778 | 0.4341 | 0.3324 | -- | 5.56 | 505,444.40 | -39.76 | -- | -67.24 | -- | 93.34 | -- | -119.63 | -- | -- | -- | 0.00 | -- | -- | -- | 14.46 | -- | -- | -- |
| Elite Pharmaceuticals Inc | 122.89m | 13.92m | 463.30m | 68.00 | 35.34 | 7.52 | 29.78 | 3.77 | 0.0122 | 0.0122 | 0.1131 | 0.0574 | 1.20 | 3.60 | 3.94 | 1,807,255.00 | 13.55 | 13.18 | 15.31 | 16.01 | 52.66 | 47.19 | 11.33 | 13.97 | 6.34 | 2.37 | 0.0681 | 0.00 | 48.42 | 36.10 | -121.46 | -- | 135.38 | -- |
| Aquestive Therapeutics Inc | 43.40m | -68.98m | 466.05m | 142.00 | -- | -- | -- | 10.74 | -0.7031 | -0.7031 | 0.4377 | -0.0338 | 0.3173 | 2.31 | 4.15 | 305,612.70 | -50.44 | -70.67 | -59.26 | -110.99 | 60.28 | 65.92 | -158.95 | -92.17 | 5.62 | -7.42 | 1.03 | -- | 13.80 | 1.82 | -460.83 | -- | -24.84 | -- |
| SIGA Technologies Inc | 172.25m | 74.47m | 475.50m | 46.00 | 6.42 | 2.34 | 6.33 | 2.76 | 1.03 | 1.03 | 2.40 | 2.84 | 0.8069 | 0.7425 | 23.63 | 3,744,558.00 | 34.88 | 27.72 | 39.21 | 33.36 | 76.29 | 86.06 | 43.23 | 44.28 | 7.24 | -- | 0.00 | 37.70 | -0.8561 | 38.99 | -13.01 | -- | 7.85 | -- |
| Zevra Therapeutics Inc | 84.39m | 35.33m | 477.40m | 59.00 | 14.35 | 3.58 | 11.74 | 5.66 | 0.591 | 0.591 | 1.54 | 2.37 | 0.3656 | -- | 6.85 | 1,430,305.00 | 15.30 | -37.95 | 17.62 | -48.83 | 93.88 | -- | 41.86 | -193.51 | 8.57 | -9.57 | 0.3153 | -- | -14.02 | 12.96 | -129.13 | -- | 196.92 | -- |
| Emergent Biosolutions Inc | 788.90m | 75.90m | 579.30m | 900.00 | 8.52 | 0.9979 | 3.33 | 0.7343 | 1.29 | 1.29 | 14.20 | 11.05 | 0.5369 | 1.06 | 5.83 | 876,555.60 | 5.17 | -5.03 | 5.90 | -6.47 | 54.58 | 49.01 | 9.62 | -9.76 | 3.15 | 1.85 | 0.5324 | -- | -0.5432 | -1.15 | 74.94 | -- | -25.06 | -- |
| CorMedix Inc | 214.30m | 162.50m | 585.40m | 64.00 | 3.62 | 1.56 | 3.51 | 2.73 | 2.05 | 2.05 | 2.97 | 4.78 | 0.5174 | 0.8901 | 2.44 | 3,348,495.00 | 39.23 | -42.85 | 48.05 | -49.82 | 92.61 | 91.93 | 75.83 | -327.99 | 1.73 | -- | 0.2802 | -- | -- | 173.65 | 61.31 | -- | 25.91 | -- |
| Rigel Pharmaceuticals Inc | 282.08m | 113.30m | 634.21m | 162.00 | 5.67 | 5.39 | 5.48 | 2.25 | 6.17 | 6.17 | 15.36 | 6.48 | 1.48 | 2.15 | 7.37 | 1,741,210.00 | 59.33 | -16.62 | 97.15 | -28.36 | 93.10 | 95.63 | 40.17 | -16.88 | 2.14 | 25.77 | 0.3368 | -- | 53.38 | 24.77 | 169.69 | -- | -22.92 | -- |
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| ASP Isotopes Inc | 8.38m | -105.56m | 709.37m | 136.00 | -- | 7.15 | -- | 84.62 | -1.43 | -1.43 | 0.1124 | 0.7932 | 0.0541 | 8.86 | 0.884 | 61,642.43 | -68.21 | -- | -85.13 | -- | 23.00 | -- | -1,261.23 | -- | 6.10 | -0.6787 | 0.5382 | -- | 857.03 | -- | -115.60 | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 338.99m | 28.55m | 722.29m | 253.00 | 31.62 | -- | 23.72 | 2.13 | 0.1404 | 0.1404 | 2.00 | -1.62 | 0.863 | -- | 3.45 | 1,339,870.00 | 7.27 | -6.08 | 11.57 | -7.13 | -- | -- | 8.42 | -11.01 | -- | 4.73 | 1.82 | -- | -20.63 | -3.89 | 100.09 | -56.87 | -54.38 | -- |
Data as of Feb 12 2026. Currency figures normalised to Emergent BioSolutions Inc's reporting currency: US Dollar USD
43.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2025 | 3.90m | 7.44% |
| Oak Hill Advisors LPas of 30 Sep 2025 | 3.61m | 6.88% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.20m | 6.09% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 2.45m | 4.66% |
| American Century Investment Management, Inc.as of 30 Sep 2025 | 2.38m | 4.54% |
| Dimensional Fund Advisors LPas of 30 Sep 2025 | 2.02m | 3.84% |
| Palisade Capital Management LPas of 30 Sep 2025 | 1.43m | 2.72% |
| Charles Schwab Investment Management, Inc.as of 30 Sep 2025 | 1.38m | 2.63% |
| Geode Capital Management LLCas of 30 Sep 2025 | 1.28m | 2.44% |
| Acadian Asset Management LLCas of 30 Sep 2025 | 1.18m | 2.24% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
